All PAH subjects were on combination therapy with a PDE5 inhibitor and endothelin receptor antagonist, and two PAH subjects were also on an inhaled prostacyclin or a prostacyclin receptor agonist. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.